McClellan v. Bayer Corp.
Supreme Court of Pennsylvania
McClellan v. Bayer Corp., 36 A.3d 590 (Pa. 2012)
614 Pa. 314; 2012 WL 284309; 2012 Pa. LEXIS 215
McClellan v. Bayer Corp.
Opinion of the Court
ORDER
AND NOW, this 1st day of February, 2012, as Petitioners’ Amended Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction replaced the initial Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction, the initial Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction is DISMISSED. Additionally, the Motion for Leave to File Reply Brief and the Motion for Leave to Supplement Application are GRANTED. Furthermore, the Amended Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction is DENIED. Finally, the Motion for Consolidation is DISMISSED AS MOOT.
Reference
- Full Case Name
- Janet McCLELLAN and William McClellan III, Individually and as the Representatives of the Estate of Megan McClellan v. BAYER CORPORATION, Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., f/k/a Berlex, Inc., f/k/a Berlex Laboratories, Inc. on its own Behalf and as Successor by Merger to Bayer Pharmaceuticals Corporation, and Bayer Pharma AG, f/k/a Bayer Schering Pharma AG
- Status
- Published